In-depth discussion on neuro therapeutics and strategic priorities for the next 18 months by Actinogen Medical Ltd CEO|Steven Gourlay , CEO, Actinogen Medical Ltd. 00:10:00
The CEO of Actinogen Medical Ltd discusses the company's focus on neuro therapeutics, recent financial highlights, and upcoming strategic priorities for the next 18 months, highlighting their lead compound Xanamem® for treating neurological diseases associated with dysregulated brain cortisol.